The value of the US infusion therapy device market is forecast to exceed $6.6bn by 2017, according to iData Research.
The report revealed that market growth will be driven by the increasing use of infusion pumps and antimicrobial mechanical valve needleless connectors, as well as the introduction of smart pumps.
iData CEO Dr Kamran Zamanian said that Medicare and major insurance companies are no longer reimbursing for vascular access associated infections.
“Facilities must absorb the costs of treating such patients and as a result, hospitals are purchasing premium-priced antimicrobial needleless connectors, making this segment the fastest-growing in the market with almost 70% growth in 2010,” said Zamanian.